Financials SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.54 USD +4.76% Intraday chart for SCYNEXIS, Inc. +6.94% -30.94%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 88.51 147.5 174 50.94 82.97 58.18 - -
Enterprise Value (EV) 1 88.51 147.5 174 50.94 82.97 58.18 58.18 58.18
P/E ratio -0.95 x -1.49 x -4.88 x -1.06 x 1.6 x -6.36 x 70 x 1.32 x
Yield - - - - - - - -
Capitalization / Revenue 731 x - 13.2 x 10 x 0.59 x 1.87 x 1.43 x 0.51 x
EV / Revenue 731 x - 13.2 x 10 x 0.59 x 1.87 x 1.43 x 0.51 x
EV / EBITDA - -2,889,865 x - -598,289 x - - - -
EV / FCF -1,651,269 x - - -603,706 x - - -2,085,336 x 4,581,172 x
FCF Yield -0% - - -0% - - -0% 0%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 9,726 19,280 28,520 32,657 37,208 37,780 - -
Reference price 2 9.100 7.650 6.100 1.560 2.230 1.540 1.540 1.540
Announcement Date 3/11/20 3/29/21 3/29/22 3/31/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.121 - 13.16 5.091 140.1 31.17 40.65 113.6
EBITDA - -51.04 - -85.15 - - - -
EBIT 1 -48.92 -51.15 -60.84 -85.76 72.67 -11.1 -1.142 72.11
Operating Margin -40,430.58% - -462.19% -1,684.48% 51.85% -35.62% -2.81% 63.48%
Earnings before Tax (EBT) 1 -53.71 -58.33 -35.95 -67.51 67.18 -9.737 -0.2726 73.64
Net income 1 -53.71 -55.18 -32.87 -62.81 67.04 -9.737 -0.6526 72.78
Net margin -44,388.43% - -249.68% -1,233.73% 47.84% -31.24% -1.61% 64.08%
EPS 2 -9.600 -5.150 -1.250 -1.470 1.390 -0.2420 0.0220 1.166
Free Cash Flow -53.6 - - -84.39 - - -27.9 12.7
FCF margin -44,296.69% - - -1,657.57% - - -68.64% 11.18%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - 17.45%
Dividend per Share - - - - - - - -
Announcement Date 3/11/20 3/29/21 3/29/22 3/31/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.516 0.597 0.687 1.323 1.557 1.524 1.13 131.5 1.761 5.797 0.303 4.242 13.22 13.47 0.8625
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -19.44 -22.3 -19.74 -21.74 -21.8 -22.48 -10.68 116.5 -10.1 -23.06 -9.793 -5.972 2.516 2.148 -8.52
Operating Margin -3,767.64% -3,734.84% -2,873.07% -1,643.08% -1,400.19% -1,475.13% -945.31% 88.63% -573.42% -397.88% -3,231.95% -140.78% 19.03% 15.95% -987.83%
Earnings before Tax (EBT) 1 -0.655 -29.24 -10.15 -13.34 -29.58 -14.43 -33.88 122.3 -1.757 -19.45 -9.414 -5.653 2.841 2.509 -7.711
Net income 1 -0.605 -29.24 -5.451 -13.34 -29.58 -14.43 -33.88 122.3 -1.757 -19.59 -9.414 -5.653 2.841 2.509 -7.711
Net margin -117.25% -4,898.32% -793.45% -1,008.69% -1,900.06% -946.78% -2,997.88% 93.01% -99.77% -337.86% -3,107% -133.26% 21.49% 18.63% -894.03%
EPS 2 -0.0200 -1.050 -0.1700 -0.3100 -0.6200 -0.2900 -0.7100 2.460 -0.0400 -0.3900 -0.1940 -0.1180 0.0340 0.0280 -0.1600
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 3/29/22 5/12/22 8/15/22 11/9/22 3/31/23 5/10/23 8/14/23 11/13/23 3/28/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -53.6 - - -84.4 - - -27.9 12.7
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 0 - - - 2 2 2
Capex / Sales - - - - - 6.42% 4.92% 1.76%
Announcement Date 3/11/20 3/29/21 3/29/22 3/31/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.54 USD
Average target price
6.875 USD
Spread / Average Target
+346.43%
Consensus
  1. Stock Market
  2. Equities
  3. SCYX Stock
  4. Financials SCYNEXIS, Inc.